Exhibitor Puma Biotechnology 07-10 - Scripps CME Connection
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Inc (PBYI) Stock Price & Performance 2023
Henry Kuo - Head of Information Technology - Puma Biotechnology, Inc. | LinkedIn
Former Puma Biotechnology exec is accused of making $1.2 million from insider trading - Los Angeles Times
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
Fillable Online Puma biotechnology, inc. form s-1/a - Biotech Due Diligence Fax Email Print - pdfFiller
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology, Inc. (PBYI) Company Information - Simply Wall St
Puma Biotechnology, Inc. (NASD:PBYI) Seasonal Chart | Equity Clock
Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Articles about Puma Biotechnology
Puma Biotechnology
Former Puma Biotechnology Executive Sentenced to More than Two Years in Prison for Insider Trading | BioSpace
Puma Biotechnology
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
